Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accommodate, accuracy, adequacy, Aid, alanine, aminotransferase, Ann, Antonio, appetite, Arch, attending, AXL, Bellmunt, bempegaldesleukin, Biden, Bio, BioNTech, biospecimen, BLA, Bristol, CAA, cabozantinib, Carlo, causality, cemiplimab, chance, childcare, children, cisplatin, Cit, combating, compartment, conjugate, contrast, count, COVID, CPI, CR, CRL, DCR, diarrhea, disparate, distancing, diverge, EEA, eganelisib, enabled, enfortumab, EP, etrumadenant, factor, FDARA, FFCR, fill, forthcoming, freestanding, Genitourinary, Gilead, governor, greatest, GU, guide, Hamilton, hazard, hear, heavily, Hedging, hepatotoxicity, highlighted, hosted, household, Hy, IDMC, injunction, KIT, laid, landscape, Lesion, lessen, leverage, linrodostat, logistic, mechanism, MER, MHRA, modulation, Monte, NaN, nationwide, neutrophil, nonredundant, Oncol, ORR, ovarian, overturning, Overview, paused, PDCO, persist, PFS, Piper, plot, poorer, presidential, pyrexia, relatlimab, reliant, remotely, rescinded, resumption, RET, San, Sandler, screening, SD, Secura, sequester, simulated, simulation, sitravatinib, skilled, SPC, splitting, stratified, Subtopic, succeed, Symposium, syngeneic, tactical, Tan, TEAE, thirteen, Tomczak, transplant, tyrosine, underwriting, underwritten, uninterrupted, unnecessary, unsatisfactorily, vedotin, VEGFR, voluntarily, waterfall, withdrew, worsen, WP
Removed:
accepting, acquirer, adapt, adult, advice, alternate, Anatomic, arrange, assessing, attempting, attest, attestation, author, Barry, biomarker, bipartisan, Brook, Cadillac, Cantor, certified, chamber, clarification, Codification, Coller, companion, comparative, concluding, concurrently, Continuation, contrary, counterfeit, creation, dated, declare, dedicate, deferring, delaying, deriving, disadvantage, discouraging, dispensed, disrupt, distributing, documented, DSCA, easily, enhancement, establishment, ethical, excise, exert, exhausted, expanding, explicit, expressed, falsifying, fashion, fellow, Fitzgerald, flexibility, follicular, gap, Gary, generating, Gilliland, Hematology, Hematopathology, IEC, illegitimate, image, IMM, impaneled, implanted, importance, improved, inactivity, influence, infused, ingredient, inhaled, injected, instilled, insured, intangible, internationally, investigative, isoform, Jeffery, journal, Kutok, leaflet, leukemia, Likewise, linked, lymphocytic, lymphoma, maker, marker, methodology, misrepresent, Modernization, modernize, neutrality, ninety, nondeductible, nonpromotional, outpatient, packaged, page, partially, pathobiology, pathology, PDMA, permissible, phenotype, platelet, poverty, practical, practitioner, prepayment, prevented, preventing, professor, promissory, proximity, radiographic, radiopharmaceutical, rarely, reassessment, rebate, recommend, redeem, relapsed, removal, remove, renewal, repayment, retrospective, revoked, run, scrutiny, servicing, settlement, shortening, slower, spur, stalled, Stony, subjecting, sublicensed, suit, supplied, sustained, sustaining, takeover, Task, tender, thereon, tracing, traditional, typical, unqualified, urge, validation, verify, vulnerability, Women, York
Filing tables
Filing exhibits
Associated INFIQ transcripts
INFIQ similar filings
Filing view
External links
EXHIBIT 32.1
STATEMENT PURSUANT TO 18 U.S.C. §1350
Pursuant to 18 U.S.C. §1350, the undersigned certifies that, to her knowledge, this Annual Report on Form 10-K for the period ended December 31, 2020 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Infinity Pharmaceuticals, Inc.
Date: March 16, 2021 | /S/ ADELENE Q. PERKINS | ||||||||||
Adelene Q. Perkins | |||||||||||
Chief Executive Officer | |||||||||||
(Principal Executive Officer) |
A signed original of this written statement required by Section 906 has been provided to Infinity Pharmaceuticals, Inc. and will be retained by Infinity Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.